Statistical Issues and Lessons Learned from COVID-19 Clinical Trials with Lopinavir-Ritonavir and Remdesivir
View ORCID ProfileGuosheng Yin, Chenyang Zhang, View ORCID ProfileHuaqing Jin
doi: https://doi.org/10.1101/2020.06.17.20133702
Guosheng Yin
Department of Statistics and Actuarial Science, The University of Hong Kong, Hong Kong
Chenyang Zhang
Department of Statistics and Actuarial Science, The University of Hong Kong, Hong Kong
Huaqing Jin
Department of Statistics and Actuarial Science, The University of Hong Kong, Hong Kong
Data Availability
The authors confirm that the data supporting the findings of this study are available within the article.
Posted June 19, 2020.
Statistical Issues and Lessons Learned from COVID-19 Clinical Trials with Lopinavir-Ritonavir and Remdesivir
Guosheng Yin, Chenyang Zhang, Huaqing Jin
medRxiv 2020.06.17.20133702; doi: https://doi.org/10.1101/2020.06.17.20133702
Subject Area
Subject Areas
- Addiction Medicine (375)
- Allergy and Immunology (690)
- Anesthesia (185)
- Cardiovascular Medicine (2774)
- Dermatology (237)
- Emergency Medicine (415)
- Epidemiology (12424)
- Forensic Medicine (10)
- Gastroenterology (786)
- Genetic and Genomic Medicine (4291)
- Geriatric Medicine (397)
- Health Economics (703)
- Health Informatics (2771)
- Health Policy (1027)
- Hematology (371)
- HIV/AIDS (882)
- Medical Education (405)
- Medical Ethics (113)
- Nephrology (455)
- Neurology (4066)
- Nursing (218)
- Nutrition (602)
- Oncology (2145)
- Ophthalmology (607)
- Orthopedics (251)
- Otolaryngology (313)
- Pain Medicine (257)
- Palliative Medicine (78)
- Pathology (480)
- Pediatrics (1151)
- Primary Care Research (471)
- Public and Global Health (6673)
- Radiology and Imaging (1457)
- Respiratory Medicine (888)
- Rheumatology (425)
- Sports Medicine (354)
- Surgery (467)
- Toxicology (57)
- Transplantation (194)
- Urology (171)